Eliem Therapeutics Inc
NASDAQ:ELYM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Y
|
Yingde Greatchem Chemicals Co Ltd
SZSE:300804
|
CN |
Eliem Therapeutics Inc
Total Equity
Eliem Therapeutics Inc
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Eliem Therapeutics Inc
NASDAQ:ELYM
|
Total Equity
$107.6m
|
CAGR 3-Years
71%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Equity
-$3.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Equity
$22.7B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Equity
$8.7B
|
CAGR 3-Years
33%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Equity
$18.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
17%
|
CAGR 10-Years
35%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Equity
$31.3B
|
CAGR 3-Years
11%
|
CAGR 5-Years
23%
|
CAGR 10-Years
24%
|
|
Eliem Therapeutics Inc
Glance View
Eliem Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Redmond, Washington and currently employs 19 full-time employees. The company went IPO on 2021-08-10. The firm focuses on developing novel therapies for neuronal excitability disorders that addresses unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the perishable and central nervous system. The firm offers two lead clinical-stage candidates: ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide (PEA) prodrug developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP). ETX-810 is being evaluated in two Phase II a clinical trial. ETX-155 is a neurosteroid gamma-aminobutyric acid type A (GABAA) receptor positive allosteric modulator (PAM) developed for major depressive disorder (MDD), perimenopausal depression (PMD) and focal onset seizures (FOS). The firm provides two programs in addition to its clinical candidates, namely Kv7.2/3 program and anxiolytic.
See Also
What is Eliem Therapeutics Inc's Total Equity?
Total Equity
107.6m
USD
Based on the financial report for Dec 31, 2023, Eliem Therapeutics Inc's Total Equity amounts to 107.6m USD.
What is Eliem Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 3Y
71%
Over the last year, the Total Equity growth was -16%. The average annual Total Equity growth rates for Eliem Therapeutics Inc have been 71% over the past three years .
